Bristol-Myers Squ…
USUSDBristol-Myers Squibb Company (MX:BMY) — Drug Manufacturers - General. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 6. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte kohta
- Veebileht
- bms.com
- Investorite suhted
- bms.com/investors.html
- Sektor
- Healthcare · Drug Manufacturers - General
- Peakontor
- PRINCETON, United States
- Tegevjuht
- Christopher S. Boerner
- Töötajad
- 32 500
- Asutatud
- 1989
- Börsil alates
- 01.03.2005 (MX:BMY)
- Ringluses olevad aktsiad
- 2.04 mld seisuga 2026-07-22
- Vabalt kaubeldavad aktsiad
- 2.04 mld
- Turukapitalisatsioon
- 128.41 mld USD
- Siseringi isikud
- 0.1%
- Institutsionaalsed investorid
- 84.87%
- Tegevusala (SIC)
- Pharmaceutical Preparations
- Õiguslik vorm
- XTIQ
- ISIN
- US1101221083
- LEI
- HLYYNH7UQUORYSJQCN42
- Väljamaksesuhe
- 54.9%
- FCF
- 11.4 mld USD45%
- Võlg
- 43.9 mld USD3.1 a FCF
- Dividendistaaž
- 54 a
- Kasum, FCF ja dividendid makstud — 12 kuu jooksul kuni 30.06.2026 (ettevõtte viimane raport).
Kirjeldus
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Börsid ja tikkerid
| Börs | Tikker | Valuuta | Hind | Tüüp |
|---|---|---|---|---|
| US USA Stocks | BMY põhinoteering | USD | 59.58 -0.20% | tavalised aktsiad |
| LSE London Stock Exchange | 0R1F IOB | GBP | — | tavalised aktsiad |
| MI Borsa Italiana (Milan) | 1BMY lisanoteering | EUR | 54.34 +1.31% | tavalised aktsiad |
| MX Mexican Stock Exchange | BMY lisanoteering | MXN | 1 088.5 +1.73% | tavalised aktsiad |
| VI Vienna Stock Exchange | BMYS lisanoteering | EUR | 52.65 +0.04% | tavalised aktsiad |
| XETRA Xetra | BRM lisanoteering | EUR | 53.04 +0.89% | tavalised aktsiad |
Dividendid
Bristol-Myers Squibb Company (BMY) maksab dividende kvartalis. Viimase 12 kuu jooksul maksti 45.2778 MXN aktsia kohta (maksed: 4). See on umbes 4.16% praegusest aktsiahinnast. Makseajaloo põhjal oodatakse järgmist ex-dividendi kuupäeva umbes 04.01.2027. Katkematu dividendiajalugu: 54 aastat.
| Ex-kuupäev | Väljamakse | Summa | % | Tüüp | Tikker |
|---|---|---|---|---|---|
| 2026-10-02 | — | 11.3195 MXN | 1.0/4.2 % | kord kvartalis | MX:BMY |
| 2026-07-02 | — | 11.3195 MXN | 1.0/4.1 % | kord kvartalis | MX:BMY |
| 2026-04-06 | — | 11.3195 MXN | 1.0/4.1 % | kord kvartalis | MX:BMY |
| 2026-01-02 | — | 11.3195 MXN | 1.0/4.1 % | kord kvartalis | MX:BMY |
| 2025-10-03 | — | 11.1398 MXN | 1.0/4.1 % | kord kvartalis | MX:BMY |
| 2025-07-03 | — | 11.1398 MXN | 1.0/4.1 % | kord kvartalis | MX:BMY |
| 2025-04-04 | — | 11.1398 MXN | 1.0/4.0 % | kord kvartalis | MX:BMY |
| 2025-01-03 | — | 11.1398 MXN | 1.0/4.0 % | kord kvartalis | MX:BMY |
| 2024-10-04 | — | 10.7804 MXN | 1.0/4.0 % | kord kvartalis | MX:BMY |
| 2024-07-05 | — | 10.7804 MXN | 1.0/3.9 % | kord kvartalis | MX:BMY |
| 2024-04-04 | — | 10.7804 MXN | 1.0/3.9 % | kord kvartalis | MX:BMY |
| 2024-01-04 | — | 10.7804 MXN | 1.0/3.8 % | kord kvartalis | MX:BMY |
| 2023-10-05 | — | 10.2414 MXN | 0.9/3.8 % | kord kvartalis | MX:BMY |
| 2023-07-06 | — | 10.2414 MXN | 0.9/3.7 % | kord kvartalis | MX:BMY |
| 2023-04-10 | — | 10.2414 MXN | 0.9/3.7 % | kord kvartalis | MX:BMY |
| 2023-01-05 | — | 10.2414 MXN | 0.9/3.6 % | kord kvartalis | MX:BMY |
| 2022-10-06 | — | 9.7024 MXN | 0.9/3.6 % | kord kvartalis | MX:BMY |
| 2022-06-30 | — | 9.7024 MXN | 0.9/2.7 % | kord kvartalis | MX:BMY |
| 2022-03-31 | — | 9.7024 MXN | 0.9/1.8 % | kord kvartalis | MX:BMY |
| 2022-01-06 | — | 9.7024 MXN | 0.9/0.9 % | kord kvartalis | MX:BMY |
Selle nädala uudised
Pressiteated ettevõtte investorite veebisaidilt, uuendatakse iga päev. Lingid viivad ettevõtte veebilehele. Pealkirjad on originaalkeeles, nagu ettevõtte veebilehel.
Suurimad omanikud
| Omanik | Osalus | Aktsiad | Aruande kuupäev |
|---|---|---|---|
| Blackrock Inc. | 8.83% | 180.38 mln | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 133.34 mln | 2026-06-30 |
| State Street Corporation | 5.01% | 102.41 mln | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.51% | 71.71 mln | 2026-06-30 |
| Charles Schwab Investmen… | 3.31% | 67.6 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 64.83 mln | 2026-06-30 |
| Geode Capital Management… | 2.76% | 56.44 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 52.92 mln | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 2.38% | 48.64 mln | 2026-05-31 |
| Vanguard Portfolio Manag… | 2.29% | 46.87 mln | 2026-06-30 |
| NORGES BANK | 1.8% | 36.87 mln | 2026-06-30 |
| Bank of America Corporat… | 1.67% | 34.05 mln | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.55% | 31.71 mln | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 27.55 mln | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 26.41 mln | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 24.96 mln | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 19.44 mln | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 14.68 mln | 2026-08-31 |
| VANGUARD CHESTER FUNDS-V… | 0.7% | 14.29 mln | 2026-06-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 11.09 mln | 2026-06-30 |
| LEUNG SANDRA (General Co… | ≈0.02% | 465 374 | 2025-03-10 |
| ELKINS DAVID VINCENT (Ch… | ≈0.01% | 159 542 | 2026-04-01 |
| BOERNER CHRISTOPHER S (C… | ≈0.01% | 146 890 | 2026-03-10 |
| HIRAWAT SAMIT (Officer) | ≈0% | 83 513 | 2025-04-25 |
| HALLER JULIA A (Director… | ≈0% | 34 079 | 2026-06-15 |
| MEYERS GREGORY SCOTT (Ch… | ≈0% | 30 361 | 2026-03-10 |
| LENKOWSKY ADAM (Officer) | ≈0% | 28 677 | 2026-05-01 |
| SHANAHAN KARIN (Officer) | ≈0% | 27 345 | 2026-04-01 |
| PLENGE ROBERT M (Officer… | ≈0% | 24 754 | 2026-03-10 |
| MASSACESI CRISTIAN (Offi… | ≈0% | 18 748 | 2026-09-09 |
Logi sisse Google